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OBJECTIVES The aim of this article is to underline the importance of this complication after endovascular
brachytherapy (EVBT) and intravascular stenting of the femoropopliteal arteries occurring in
a running randomized trial.
BACKGROUND Endovascular brachytherapy has been proposed as a promising treatment modality to reduce
restenosis after angioplasty. However, the phenomenon of late acute thrombotic occlusion
(LATO) in patients receiving EVBT after stenting is of major concern.
METHODS In an ongoing prospective multicenter trial, patients were randomized to undergo EVBT
(iridium 192; 14 Gy at a depth of the radius of the vessel 2 mm) after percutaneous
recanalization of femoropopliteal obstructions. Of the 204 patients who completed the six
months follow-up, 94 were randomized to EVBT.
RESULTS Late acute thrombotic occlusion occurred exclusively in 6 of 22 patients (27%) receiving
EVBT after intravascular stenting and always in concomitance with reduction of antithrom-
botic drug prevention (clopidogrel). Conversely, none of the 13 patients with stents and
without EVBT (0%; p 0.05) and none of the 72 patients (0%; p 0.01) undergoing EVBT
after simple balloon angioplasty presented LATO.
CONCLUSIONS Late thrombotic occlusion occurs not only in patients undergoing EVBT after percutaneous
coronary recanalization but also after stenting of the femoropopliteal arteries and may
compromise the benefits of endovascular radiation. The fact that all our cases with LATO
occurred concomitantly with stopping clopidogrel may indicate a possible rebound mecha-
nism. An intensive and prolonged antithrombotic prevention is probably indicated in these
patients. (J Am Coll Cardiol 2003;41:409–12) © 2003 by the American College of
Cardiology Foundation
The phenomenon of restenosis after angioplasty was antic-
ipated by Gru¨ntzig and Hopff (1) 30 years ago at the time
they first applied balloon angioplasty for lower limb arteries.
Further large clinical series after angioplasty of the lower
limb arteries, and numerous reports during the last two
decades involving patients undergoing percutaneous trans-
luminal coronary angioplasty (PTCA), have confirmed the
clinical and economical impact of restenosis. The magni-
tude of restenosis after PTCA and after angioplasty of the
lower limb arteries varies according to the diagnostic meth-
ods used (clinical, quantitative angiography, intravascular
ultrasound) and has been reported in a range between 15%
and 50% (2–6). Through introduction of coronary stents,
the incidence of restenosis after PTCA has only been
moderately reduced to 20% to 30% (7). The use of intra-
vascular stenting at the femoropopliteal level to prevent
restenosis remains controversial (8–11).
In animal studies and in patients, one of the most
promising modalities to reduce restenosis seems to be the
application of endovascular brachytherapy (EVBT) (12,13).
Although EVBT was also first applied after angioplasty of
the lower limb arteries in the early 1990s (12), few prospec-
tive studies have been published on the efficacy of brachy-
therapy after angioplasty of the femoropopliteal arteries as a
strategy to prevent restenosis. In a recently published
randomized trial on EVBT after angioplasty of very long
obstructions of the femoropopliteal arteries, the incidence of
restenosis at six months follow-up could be significantly
reduced from 53% to 28% in the group of patients receiving
endovascular gamma-irradiation (14). The phenomenon of
late acute thrombotic occlusion (LATO) has been reported
in larger PTCA trials with an incidence of 6% to 9%
(15,16), and in one single nonrandomized pilot study of
patients undergoing EVBT after femoral stenting (17).
We decided to report on LATO in femoropopliteal
arteries in relation to EVBT and stenting based on the
results of the preliminary analysis of our ongoing, random-
ized, four-arm, multicenter trial, because of the high rele-
vance of this phenomenon which may challenge the benefit
of vascular radiation.
METHODS
The aim of our ongoing multicenter trial is to evaluate the
effect of a combined prevention strategy (physical and
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chemical) on restenosis after percutaneous recanalization of
the femoropopliteal arteries. The protocol includes a ran-
domized, unblinded comparison of the efficacy of EVBT
(iridium 192) performed immediately after angioplasty and
a blinded comparison of a medical prevention using probu-
col randomized versus placebo (18).
All patients 50 years, with chronic claudication (Fon-
taine II A and B), and with arterial stenosis 50% or total
occlusion at the femoropopliteal level, who are referred to
our four vascular centers were eligible for the trial. Utiliza-
tion of stenting during the angioplasty procedure because of
unstable dissection or unsatisfactory results after balloon
dilation is left to the discretion of the interventionist.
Following the initial notification of the Food and Drug
Administration in 1998 of cases with LATO in patients
undergoing intracoronary stenting and brachytherapy (19),
our protocol mandates that patients receiving stenting and
EVBT are treated with a double antiplatelet regimen
(aspirin 100 mg and clopidogrel 75 mg/day) for an unlim-
ited time after the procedure. The appropriate institutional
review boards approved the protocol, and all patients gave
written informed consent.
High-dose rate EVBT was performed using gamma-
irradiation with a 192Ir-source. A 5F closed-tip, noncen-
tered applicator catheter (Nucletron, Veenendaal, The
Netherlands) was advanced through the 6F sheath and
placed in the balloon-treated lesion so that the tip of the
catheter reaches 1.5 cm distal to the distal end of the
interventional length (IL). The active source length corre-
sponded to the IL plus 1.5 cm on the distal and proximal
end. The dose distribution was calculated by means of a
computer-assisted planning system (Plato-BPS, version
13.2, Nucletron) with a 2.5-mm stepping source. The
reference dose of 14 Gy was applied in a depth from the
source given by the radius from the center of the dilated
segment plus 2 mm. Marks on the dummy wire defined the
IL and the length of the irradiated segment. After its
definition, the dummy wire was removed. The application
catheter was connected to the afterloader, and the source
was advanced into the applicator.
Follow-up examinations include clinical, noninvasive ex-
amination (ankle brachial pressure index) as well as duplex
scanning after one day, at three and six months after
intervention.
Duplex scanning, a well validated method to measure
significant vascular obstructions at the femoropopliteal level,
is performed according to the criteria of Ja¨ger et al. (20) by
the same operator in each of the four vascular centers, using
an Acuson Sequoia 256 (Mountain View, California) unit,
and measuring the ratio between the peak systolic Doppler
velocities of the dilated segment and at 1 to 2 cm proximal
to the lesion.
The primary end point of the trial is to quantify the
incidence of 50% restenosis at six months follow-up. Late
acute thrombotic occlusion is defined as an acute occlusion
of the dilated vascular segment occurring beyond the three
months follow-up in a patient without any evidence of
progression or restenosis at the preceding duplex scanning.
Statistical comparison between the occurrence of LATO in
the different subgroups was calculated by the Student t test.
RESULTS
A total of 204 patients have reached the predefined six
months follow-up period and are available for an interim
analysis of the unblinded part of the protocol (EVBT vs. no
EVBT). Of the 204 patients, 94 underwent EVBT imme-
diately after angioplasty. Of these 94 patients, 22 patients
with EVBT needed stenting. The LATO of the dilated
segment occurred in 6 of the 22 patients (27%). Conversely,
none of the 13 patients (0%; p  0.05) undergoing stents
without EVBT presented LATO. Furthermore, none of the
72 patients (0%; p  0.01) undergoing EVBT after only
balloon angioplasty and none of the 97 patients (0%; p 
0.01) without EVBT presented LATO. Late acute throm-
botic occlusion was not seen in any of the patients taking
clopidogrel and undergoing EVBT after stenting.
Figure 1 shows the restenosis rate at six months and the
corresponding proportion of LATO in the two groups of
patients undergoing stenting with and without EVBT. The
restenosis rate in patients undergoing stenting with and
without EVBT was similar (41% and 43%, respectively).
Late acute thrombotic occlusion occurred exclusively in
patients receiving EVBT after stenting (Fig. 1, black area),
with major impact on the rate of restenosis in this group of
patients. If LATO could have been avoided in these
patients with stent and with EVBT, given the absence of an
underlying restenotic process after thrombus extraction
and/or lysis, as indicated in the following text, the restenosis
rate would have decreased from 40% to 12% (Fig. 1).
Late acute thrombotic occlusion occurred at 16, 17, 18,
and 23 weeks after stenting and EVBT. In a further case,
LATO occurred 68 weeks after percutaneous recanalization.
All cases of acute occlusion occurred concomitantly with the
reduction of the antithrombotic drug prevention, because of
gastric side effects (three patients) or noncompliance (three
patients). Clopidogrel was stopped between two and six
weeks before the sudden occlusion of the stented segment.
Late acute thrombotic occlusion was associated with reap-
pearance of claudication and was documented by angiogra-
phy and in one case by duplex ultrasound. Four patients
underwent thrombolysis with urokinasis infusion overnight;
another patient was treated with thrombus extraction fol-
lowed by glycoprotein IIb/IIIa infusion. All five patients
Abbreviations and Acronyms
EVBT  endovascular brachytherapy
IL  interventional length
LATO  late acute thrombotic occlusion
PTCA  percutaneous transluminal coronary angioplasty
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had a final result of complete patency with no evidence of
restenosis and no need of re-angioplasty. The sixth patient
with minor symptoms was treated medically.
All six patients with LATO had three patent run-off
vessels, compared with a mean value of two patent run-off
vessels for the whole trial. The baseline severity and length
of the obstruction varied between 75% and 100% and from
4.0 to 6.5 cm, respectively, and were comparable to that in
the overall study population.
DISCUSSION
The preliminary analysis of our randomized, multicenter
trial shows that the benefit of EVBT may be challenged by
the occurrence of LATO, which in our series was observed
exclusively in patients treated by stenting and EVBT. To
our knowledge, this is the first report that demonstrates in
a large randomized trial the impact of LATO on the
long-term follow-up after EVBT in patients undergoing
stents of the lower limb arteries.
There is limited experience with intravascular stenting
after angioplasty of the femoropopliteal arteries, with con-
troversial results (8–11), in contrast to the positive experi-
ence for coronary stenting, which moderately reduces the
restenosis rate compared with simple balloon PTCA (7).
Endovascular brachytherapy may be a promising treat-
ment modality to reduce restenosis after angioplasty, as
recently reported in some randomized coronary trials (13)
and in one randomized trial on peripheral percutaneous
transluminal angioplasty (14).
An unusual rate of LATO after brachytherapy was first
reported in 1998 in the interim analysis of the first trials of
patients undergoing EVBT after intracoronary stenting
(15,16), and was recently reported in a pilot study at the
femoropopliteal level (17). The pathogenesis of LATO after
stenting and EVBT is probably related to the same mech-
anism of action intended to reduce restenosis (i.e., reduction
of neointimal proliferation). The same mechanism prevents
endothelial regeneration to cover the stent struts, which
usually occurs within two to three weeks after stenting
without irradiation. The fact that five of our patients with a
LATO could be treated by either thrombolysis or thrombus
aspiration confirms the hypothesis that these occlusions may
be attributed to thrombosis. This hypothesis is supported by
the fact that all these patients with LATO presented normal
patent run-off vessels.
To avoid this vascular complication after brachytherapy,
the interventionist may limit the application of EVBT to
nonstented arteries. Alternatively, a more intensive and
prolonged antithrombotic prevention should be prescribed,
as recently proposed for coronary revascularization (16–22).
In fact, if LATO could have been avoided in our group of
patients undergoing brachytherapy after stenting, the reste-
nosis rate would have fell from 40% to 12% (Fig. 1). Because
stenting was usually used in patients with suboptimal results
after balloon angioplasty, we cannot exclude that these
patients were prone to LATO due to the complication of
the intervention. This consideration may be applicable also
to the unusually high rate of restenosis found in the
subgroup of patients with intravascular stenting without
EVBT.
All our cases of LATO occurred concomitantly with a
reduction of the antithrombotic drug prevention and may
indicate that platelet recruitment and thrombus formation
which occur in non–re-endothelialized irradiated stents are
not prevented sufficiently (23). Our finding of a case with
acute occlusion immediately after stopping clopidogrel 68
weeks after intravascular stenting and EVBT leaves open
the question of the necessity of a double antithrombotic
prevention beyond the six-month threshold after EVBT
(22). Further randomized studies are needed to clarify this
problem. Patient compliance and side effects of this long-
term secondary prevention may be limiting factors, as
observed in our cases.
Our findings of a high incidence of LATO after stent and
Figure 1. Restenosis rate at six-month follow-up in patients with stent implantation with and without brachytherapy. The black area corresponds to the
rate of patients with late thrombotic occlusion.
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EVBT may have clinically relevant implications; therefore,
interventionists should be aware of this important compli-
cation which occurs also in the peripheral circulation,
especially when a long-term double antithrombotic preven-
tion with aspirin and clopidogrel is not assured.
The crucial answer to the question whether our combined
physical and chemical prevention strategy will have a rele-
vant impact on restenosis will be available only at the time
of complete inclusion and follow-up of our randomized
trial.
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APPENDIX
Other investigators of the Percutaneous versus Aspirin
versus Probacol Study are as follows: J. Bernier and L.
Cozzi, Ospedale San Giovanni, Bellinzona; Ch. Von Briel,
Department of Radiation Oncology, University Hospital,
Berne; U.-M. Lu¨tolf and P. Ju¨hlke, Department of Radia-
tion Oncology, University Hospital, Zurich; Ch. Land-
mann, Department of Radiation Oncology, University Hos-
pital, Basel; R. Canevascini, Division of Angiology,
University Hospital Basel, Switzerland.
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